Format

Send to:

Choose Destination
See comment in PubMed Commons below
JACC Cardiovasc Imaging. 2013 Dec;6(12):1327-41. doi: 10.1016/j.jcmg.2013.09.014.

The advancing clinical impact of molecular imaging in CVD.

Author information

  • 1Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • 2Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Center for Molecular Imaging Research and Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: fjaffer@mgh.harvard.edu.

Abstract

Molecular imaging seeks to unravel critical molecular and cellular events in living subjects by providing complementary biological information to current structural clinical imaging modalities. In recent years, molecular imaging efforts have marched forward into the clinical cardiovascular arena, and are now actively illuminating new biology in a broad range of conditions, including atherosclerosis, myocardial infarction, thrombosis, vasculitis, aneurysm, cardiomyopathy, and valvular disease. Development of novel molecular imaging reporters is occurring for many clinical cardiovascular imaging modalities (positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging), as well as in translational platforms such as intravascular fluorescence imaging. The ability to image, track, and quantify molecular biomarkers in organs not routinely amenable to biopsy (e.g., the heart and vasculature) open new clinical opportunities to tailor therapeutics based on a cardiovascular disease molecular profile. In addition, molecular imaging is playing an increasing role in atherosclerosis drug development in phase II clinical trials. Here, we present state-of-the-art clinical cardiovascular molecular imaging strategies, and explore promising translational approaches positioned for clinical testing in the near term.

Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

(158)Gd-ESMA; (18)F-fluorodeoxyglucose; (18)F-sodium fluoride; AS; AT1R; CAC; CEA; CMR; CT; DVT; FDA; FDG; Food and Drug Administration; ICG; LDL; LV; MI; MMP; MRI; NIRF; NaF; OFDI; OTW; PC; PET; RAAS; SUV; TBR; USPIO; aneurysm; angiotensin II type 1 receptor; aortic stenosis; atherosclerosis; cardiac magnetic resonance; carotid endarterectomy; computed tomography; coronary artery calcium; deep vein thrombosis; gadolinium-labeled elastin-specific magnetic resonance contrast agent; heart failure; high-sensitivity C-reactive protein; hsCRP; indocyanine green; left ventricle/ventricular; low-density lipoprotein; magnetic resonance imaging; matrix metalloproteinase; molecular imaging; myocardial infarction; near-infrared fluorescence; optical frequency domain imaging; over-the-wire; perfusion catheter; positron emission tomography; renin-angiotensin-aldosterone system; standardized uptake value; target-to-background ratio; thrombosis; ultrasmall superparamagnetic particles of iron oxide; valvular disease; vascular injury

PMID:
24332285
[PubMed - indexed for MEDLINE]
PMCID:
PMC3876961
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk